GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Book Value per Share

Regenxbio (Regenxbio) Book Value per Share : $7.08 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Book Value per Share?

Regenxbio's book value per share for the quarter that ended in Dec. 2023 was $7.08.

During the past 12 months, Regenxbio's average Book Value Per Share Growth Rate was -40.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -11.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Regenxbio was 25.80% per year. The lowest was -11.10% per year. And the median was 13.90% per year.

Regenxbio's current price is $16.17. Its book value per share for the quarter that ended in Dec. 2023 was $7.08. Hence, today's PB Ratio of Regenxbio is 2.28.

During the past 11 years, the highest P/B Ratio of Regenxbio was 9.14. The lowest was 1.07. And the median was 2.81.


Regenxbio Book Value per Share Historical Data

The historical data trend for Regenxbio's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Book Value per Share Chart

Regenxbio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.17 10.08 17.85 11.92 7.08

Regenxbio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.92 10.70 9.30 8.25 7.08

Competitive Comparison of Regenxbio's Book Value per Share

For the Biotechnology subindustry, Regenxbio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's PB Ratio distribution charts can be found below:

* The bar in red indicates where Regenxbio's PB Ratio falls into.



Regenxbio Book Value per Share Calculation

Regenxbio's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(311.74-0.00)/44.05
=7.08

Regenxbio's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(311.74-0.00)/44.05
=7.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Regenxbio  (NAS:RGNX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Regenxbio Book Value per Share Related Terms

Thank you for viewing the detailed overview of Regenxbio's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio (Regenxbio) Business Description

Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
Executives
Kenneth T. Mills director, officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola officer: Chief Medical Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox director, 10 percent owner C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas officer: Senior VP, General Counsel C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson officer: SVP of Technical Operations C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos officer: Chief Scientific Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo officer: Chief Medical Officer C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse director C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809